SCHEMBL4584839

SCHEMBL4584839

CC(C)(N)C(=O)NS(=O)(=O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.55
ALDH1A1 P00352 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
LARS1 Q9P2J5 1/20 0.49
CA2 P00918 3/20 0.49
KDM4E B2RXH2 2/20 0.47
PTGS1 P23219 2/20 0.47
PTGS2 P35354 2/20 0.47
BCAT1 P54687 1/20 0.47
CA1 P00915 2/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
LMNA P02545 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13764330 0.85 PPARA (0.57) PPARAALDH1A1CYP2C9CYP2C19LARS1
SCHEMBL2746052 0.83 HTT (0.62) ALDH1A1CA2BCAT1CA1KMT2A
SCHEMBL3531889 0.82 PPARA (0.55) PPARAALDH1A1CYP2C9CYP2C19LARS1
SCHEMBL5543693 0.79 PPARA (0.52) PPARAALDH1A1CYP2C9CYP2C19LARS1
SCHEMBL14278270 0.77 PPARA (0.56) PPARACYP2C19LARS1CA2KDM4E
SCHEMBL29317683 0.76 PPARA (0.59) PPARALARS1CA2KDM4EPTGS1
SCHEMBL19267848 0.75 ALDH1A1 (0.52) PPARAALDH1A1CYP2C9CYP2C19CA2
SCHEMBL209632 0.75 DHFR (0.66) CA2KDM4EPTGS1PTGS2BCAT1
SCHEMBL370189 0.75 CA2 (0.56) LARS1CA2KDM4EPTGS1PTGS2
SCHEMBL14278273 0.74 PPARA (0.48) PPARAALDH1A1CYP2C19LARS1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283479-B2 CXCR2 inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-10-09 US disclosed
US-20080090854-A1 CXCR2 INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090854-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR4 PPARA 2456/4885ALDH1A1 1443/4885CYP2C9 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.